Actively Recruiting
Evaluating Sutetinib Maleate Capsules for Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Uncommon EGFR Mutations
Led by Teligene US · Updated on 2026-11-02
66
Participants Needed
24
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy of sutetinib maleate capsules for treating participants with locally advanced or metastatic non-small cell lung cancer NSCLC that have uncommon EGFR mutations. Sutetinib is an investigational drug that works by irreversibly inhibiting the EGFR tyrosine kinase, a protein involved in cell growth and survival. The study focuses on how well sutetinib maleate capsules work specifically for this subgroup of NSCLC patients. Participants will receive sutetinib maleate capsules orally, preferably with food, at doses directed by the investigators. The treatment is given in 28-day cycles. This is an open-label, single-arm study where all participants will receive the investigational drug. The study is designed to assess both efficacy and safety over an extended period. During the study, participants will be closely monitored with assessments including tumor response evaluations using objective response rate ORR up to approximately 32 months after starting the drug. Additional measurements will include duration of response, disease control rate, progression-free survival, overall survival, and various pharmacokinetic parameters. Safety is carefully tracked through reports of adverse events and reactions. The total participation period may last up to about 32 months from the first dose.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Research Team
X
Xiaoyang Xia
D
Dawei Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here